STOCK TITAN

Moderna (MRNA) president sells 53,336 shares after option exercises

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. President Stephen Hoge reported an exercise-and-sale transaction in company stock. On May 15, 2026, he exercised stock options to acquire a total of 53,336 shares of common stock at an exercise price of $19.15 per share and sold 53,336 shares of common stock at an average price of $48.40 per share in open-market transactions. The filing notes that the reported transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. After these transactions, Hoge directly held 1,477,997 shares of Moderna common stock, along with additional indirect holdings of 151,933 shares held by a family trust and 4,116 shares held through Valhalla, LLC.

Positive

  • None.

Negative

  • None.
Insider Hoge Stephen
Role President
Sold 53,336 shs ($2.58M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 37,226 $0.00 --
Exercise Stock Option (Right to Buy) 16,110 $0.00 --
Exercise Common Stock 37,226 $19.15 $713K
Exercise Common Stock 16,110 $19.15 $309K
Sale Common Stock 53,336 $48.40 $2.58M
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 74,452 shares (Direct, null); Common Stock — 1,515,223 shares (Direct, null); Common Stock — 4,116 shares (Indirect, By Valhalla, LLC)
Footnotes (1)
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. This option is fully vested and exercisable.
Shares sold 53,336 shares Common stock sold on May 15, 2026 at $48.40
Sale price $48.40 per share Average price for 53,336 common shares sold
Shares acquired via option exercise 53,336 shares Common shares from stock option exercises at $19.15
Option exercise price $19.15 per share Exercise price for stock options converted to common stock
Direct holdings after transactions 1,477,997 shares Common stock directly owned by Stephen Hoge after May 15, 2026
Indirect trust holdings 151,933 shares Common stock held by a family trust for spouse and children
Indirect LLC holdings 4,116 shares Common stock held indirectly through Valhalla, LLC
10b5-1 plan adoption date November 13, 2025 Date the Rule 10b5-1 trading plan governing this sale was adopted
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Section 16 beneficial ownership regulatory
"The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein."
Stock Option (Right to Buy) financial
"Security title is reported as Stock Option (Right to Buy) with an exercise price of $19.1500."
derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"Holdings are reported as indirect with nature of ownership By Trust and By Valhalla, LLC."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hoge Stephen

(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026M(1)37,226A$19.151,515,223D
Common Stock05/15/2026M(1)16,110A$19.151,531,333D
Common Stock05/15/2026S(1)53,336D$48.41,477,997D
Common Stock4,116IBy Valhalla, LLC
Common Stock151,933IBy Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$19.1505/15/2026M(1)37,226 (3)08/10/2026Common Stock37,226$074,452D
Stock Option (Right to Buy)$19.1505/15/2026M(1)16,110 (3)08/10/2026Common Stock16,110$032,220D
Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.
2. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
3. This option is fully vested and exercisable.
/s/ James Dillon, as Attorney-in-Fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Moderna (MRNA) President Stephen Hoge report?

Stephen Hoge reported exercising stock options and selling Moderna shares. He acquired 53,336 common shares at a $19.15 exercise price and sold 53,336 shares at an average price of $48.40, all on May 15, 2026, under a Rule 10b5-1 plan.

How many Moderna (MRNA) shares did Stephen Hoge sell and at what price?

Stephen Hoge sold 53,336 shares of Moderna common stock. The reported average sale price was $48.40 per share in open-market transactions on May 15, 2026, according to the Form 4 insider trading report.

What stock options did Stephen Hoge exercise in this Moderna (MRNA) Form 4?

Stephen Hoge exercised stock options covering 53,336 shares of Moderna common stock. The options had an exercise price of $19.15 per share and were reported as fully vested and exercisable at the time of the May 15, 2026 transactions.

How many Moderna (MRNA) shares does Stephen Hoge hold after the reported transactions?

After the reported transactions, Stephen Hoge directly held 1,477,997 Moderna common shares. He also had indirect holdings of 151,933 shares through a family trust and 4,116 shares through Valhalla, LLC, as disclosed in the Form 4 filing.

Was Stephen Hoge’s Moderna (MRNA) stock sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, providing structure and reducing the significance of trade timing.

What indirect Moderna (MRNA) holdings are reported for Stephen Hoge?

The Form 4 reports 151,933 Moderna shares held by a trust for the benefit of Stephen Hoge’s spouse and children, and 4,116 shares held through Valhalla, LLC. Hoge disclaims Section 16 beneficial ownership of these securities except for any pecuniary interest.